On Thursday, Dec. 20, Senator Edward Markey (D-Massachusetts), a member of the U.S. Senate’s Environment and Public Works Committee, called on the U.S. Food and Drug Administration (FDA) to conduct an investigation into the allegations raised by the Reuters article published late last week. This came on the heels of Health Canada taking a strong stand in the talc safety battle.
The Dec. 14 article says that Johnson & Johnson was aware its talc powder was “sometimes tainted with carcinogenic asbestos” and they kept that information from regulators and the general public. Talc and asbestos are naturally occurring minerals, found in close proximity to each other in the earth.
Beasley Allen stands with Senator Markey in his quest for the truth. Due to the talc litigation Beasley Allen lawyers have known about the internal studies prepared for Johnson & Johnson. The jurors who have awarded billions of dollars of compensation to women who have been diagnosed with ovarian cancer as a result of the carcinogen have seen these same documents.
Earlier this week we published a rebuttal to Johnson & Johnson CEO Alex Gorsky’s claims on a CNBC broadcast, addressing reports from major media outlets that his company has known for decades that its talc-based baby powder contains traces of asbestos, and the resulting $50 billion drop in market value of the company’s stock.
Ted Meadows of the Beasley Allen law firm, a leader of the trial team in the ongoing talc litigation, and Leigh O’Dell, an attorney at the Beasley Allen law firm and co-chair of the plaintiffs’ committee currently in consolidated multidistrict litigation against J&J, know without any doubt that long-term genital application of the company’s talcum-based products has led to ovarian cancer in thousands of U.S. women.
Beasley Allen lawyers are calling on Johnson & Johnson to remove its talc-based Johnson’s Baby Powder from the market, or at a bare minimum, provide an adequate warning label to alert consumers of the dangers of genital application and the strong association with ovarian cancer.